GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, has entered into a warrant inducement agreement with an existing institutional investor. Under the terms, the investor will immediately exercise existing warrants to purchase up to 5,697,628 shares of common stock at an exercise price of $0.64 per share, generating gross cash proceeds of approximately $3,646,482 before deducting financial advisor fees and other expenses. The company intends to use the net proceeds for working capital and general corporate purposes, which is crucial as it advances its lead programs.
In consideration for the immediate exercise, the investor will receive new unregistered warrants to purchase up to 11,395,256 shares of common stock. These new warrants have an exercise price of $0.64, become exercisable upon shareholder approval of the underlying shares, and expire five years after that approval date. The closing is expected on or about August 27, 2026, subject to customary conditions.
This transaction provides GeoVax with immediate capital to support its pipeline, which includes GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The company plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, addressing global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a Phase 1/2 trial in advanced head and neck cancer and is moving into combination strategies, including neoadjuvant and first-line settings.
The warrant inducement is a common financing strategy for clinical-stage biotech companies, allowing them to raise capital quickly while providing existing investors with additional upside potential. For GeoVax, this funding is timely as it prepares for late-stage trials and seeks to strengthen its balance sheet. The company maintains a global intellectual property portfolio and continues to evaluate strategic partnerships and funding opportunities.
The private placement relies on exemptions under Section 4(a)(2) of the Securities Act and Regulation D, meaning the securities are not registered and cannot be resold unless registered or exempt. This press release does not constitute an offer to sell or a solicitation to buy these securities.
GeoVax's forward-looking statements highlight risks such as clinical trial outcomes, regulatory approvals, and the need for additional capital. The company has filed periodic reports with the SEC detailing these risks, and it undertakes no obligation to update forward-looking statements except as required by law.
